Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
268.2 SAR | -2.97% | -5.56% | -5.56% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- With an expected P/E ratio at 42.51 and 35.02 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.56% | 25.03B | C+ | ||
+25.52% | 88.99B | C+ | ||
-24.52% | 74.82B | B- | ||
+4.31% | 17.88B | A- | ||
-14.25% | 16.43B | B | ||
+2.97% | 15.77B | A- | ||
+70.11% | 13.09B | C- | ||
+79.20% | 13.21B | C+ | ||
+40.44% | 12.9B | B- | ||
+24.51% | 12.7B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4013 Stock
- Ratings Dr. Sulaiman Al Habib Medical Services Group Company